This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


AbbVie Inc.

Drug Names(s): ABT-165

Description: ABT-165 is a dual-variable domain immunoglobulin that targets VEGF and DLL4. DLL4 is a notch pathway ligand involved in angiogenesis and maintenance of tumor stem cells. The dual activity of ABT-165 is designed to address the emerging clinical challenge of tumor resistance to anti-VEGF therapies.

ABT-165 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug